Patents Assigned to TESARO, Inc.
  • Combination therapies for treating cancer
    Patent number: 12156872
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: December 3, 2024
    Assignees: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • COMBINATION THERAPIES FOR TREATING CANCER
    Publication number: 20240226082
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 11, 2024
    Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • Methods of treating ovarian cancer
    Patent number: 12005057
    Abstract: The present invention provides methods of administering a PARP inhibitor to a cancer patient.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: June 11, 2024
    Assignee: TESARO, INC.
    Inventors: Mary Lynne Hedley, Robert Martell
  • Methods of treating cancer with anti-TIM-3 antibodies
    Patent number: 11926665
    Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: March 12, 2024
    Assignee: TESARO, INC.
    Inventors: Dmitri Bobilev, Andrew R. Ferguson, Kristen Anne McEachern, Jing Wang
  • Combination therapies and uses thereof
    Patent number: 11801240
    Abstract: The present disclosure relates to combination therapies containing one or more PARP inhibitors and one or more angiogenesis inhibitor. Also described herein are therapeutic uses of such combination therapies for treating various disorders and conditions. The combination therapies and uses thereof can be useful for preventing tumor cell growth, preventing tumor metastasis, inducing an immune response or enhancing an immune response.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: October 31, 2023
    Assignee: Tesaro, Inc.
    Inventors: Keith W. Mikule, Zebin Wang, Yinghui Zhou
  • Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
    Patent number: 11753472
    Abstract: Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM 3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: September 12, 2023
    Assignees: Tesaro, Inc., Anaptysbio, Inc.
    Inventors: David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
  • Niraparib formulations
    Patent number: 11730725
    Abstract: The present invention relates to pharmaceutical tablet compositions comprising the compound niraparib as an active pharmaceutical ingredient, suitable for oral administration as well as to methods for their preparation. Also described herein are tablet compositions containing niraparib formed by the disclosed methods, and therapeutic uses of such tablet compositions for treating various disorders and conditions.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 22, 2023
    Assignee: Tesaro, Inc.
    Inventors: Simon McGurk, Padma Narayan, Aleksandar Rajlic
  • Niraparib compositions
    Patent number: 11673877
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: June 13, 2023
    Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.
    Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
  • Combination therapies for treating cancer with niraparib and PD-1 inhibitors
    Patent number: 11661453
    Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly[ADP-ribose] polymerase (PARP) signaling.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 30, 2023
    Assignee: Tesaro, Inc.
    Inventors: Keith W. Mikule, Kaiming Sun, Jing Yu Wang, Zebin Wang
  • Methods of manufacturing of niraparib
    Patent number: 11629137
    Abstract: Disclosed herein are methods and processes of preparing niraparib and pharmaceutically acceptable salts thereof, and intermediates and their salts useful for the synthesis of niraparib.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: April 18, 2023
    Assignee: Tesaro, Inc.
    Inventors: Alistair Stewart, Anthony Joseph Toto, Frank Xing Chen, George Wu
  • Combination therapies for treating cancer
    Patent number: 11622961
    Abstract: The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 11, 2023
    Assignee: Tesaro, Inc.
    Inventors: Kaiming Sun, Jing Yu Wang, Zebin Wang
  • METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES
    Publication number: 20220319704
    Abstract: Described herein are methods, systems, devices and computer program products for characterizing or identifying a type of cancer. Also described are methods of treating a characterized or identified chancer. For example, certain methods may be used to characterize a homologous recombination deficiency status of a cancer.
    Type: Application
    Filed: May 6, 2020
    Publication date: October 6, 2022
    Applicant: TESARO, INC.
    Inventors: Bin FENG, Hailei ZHANG, Jaegil KIM
  • Methods of treating cancer with anti-PD-1 antibodies
    Patent number: 11407830
    Abstract: The present invention provides methods of administering certain PD-1 binding agents to patients having cancer. Dosage regimens for compositions comprising a PD-1 binding agent are also explicitly provided.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: August 9, 2022
    Assignee: Tesaro, Inc.
    Inventors: David Jenkins, Haley A Laken, Ellie Im, Allene Diaz, Sharon Lu
  • Methods of manufacturing of niraparib
    Patent number: 11161834
    Abstract: Disclosed herein are methods and processes of preparing niraparib and pharmaceutically acceptable salts thereof, and intermediates and their salts useful for the synthesis of niraparib.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 2, 2021
    Assignee: Tesaro, Inc.
    Inventors: Alistair Stewart, Anthony Joseph Toto, Frank Xing Chen, George Wu
  • Antibodies directed against programmed death-1 (PD-1)
    Patent number: 11155624
    Abstract: The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: October 26, 2021
    Assignees: ANAPTYSBIO, INC., Tesaro, Inc.
    Inventors: David J. King, Marilyn Kehry, Baochuan Huang
  • Niraparib compositions
    Patent number: 11091459
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 17, 2021
    Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.
    Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
  • Niraparib compositions
    Patent number: 10829476
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 10, 2020
    Assignee: Tesaro, Inc.
    Inventors: George Wu, John Chaber
  • COMBINATION THERAPIES FOR TREATING CANCER
    Publication number: 20200299387
    Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: September 28, 2018
    Publication date: September 24, 2020
    Applicant: Tesaro, Inc.
    Inventors: Keith W. MIKULE, Kaiming SUN, Jing Yu WANG, Zebin WANG
  • COMBINATION THERAPIES FOR TREATING CANCER
    Publication number: 20200289493
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 17, 2020
    Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson